logo
  

Two Harbors Investment Names Robert Rush Chief Risk Officer - Quick Facts

Two Harbors Investment Corp. (TWO) said that, effective January 1, 2015, Robert Rush would assume the role of the company's Chief Risk Officer.

Paul Richardson, who has served as the company's Chief Risk Officer over the past several years, will remain in his role as Partner and Chief Risk Officer for Pine River Capital Management L.P., the parent of the company's external manager.
Rush has served as Two Harbors' Managing Director, Risk Management, since September 2013. Prior to joining the company, he held a variety of positions at UBS AG in New York.

During 2013, he was a Managing Director and Director of Risk Strategy for the Non-Core and Legacy Group, the unit established to oversee UBS' exit from capital-inefficient businesses.

From 2009 to 2012, he served as Head of Risk Analytics for the StabFund Investment Management Group. From 2007 to 2008, Rush served as the Head CDO and Esoteric Asset Trader for the UBS Workout Group. From 2006 to 2007, he co-managed the ABS/CMBS Derivatives Structuring Team within the Global CDO Group.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT